An Open-Label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to less than 11 Years: a Long Term Study.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms HIP
- Sponsors AstraZeneca
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 13 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to clinicaltrials.gov record.